News | August 17, 2012

Xeridiem Designs Implantable Biopolymer Delivery Device to Treat Dilated Cardiomyopathy

Development services aids LoneStar Heart Inc. with new heart failure treatment

August 17, 2012 —Xeridiem, a vertically integrated OEM that designs, develops and manufactures complex single-use medical devices, announced it will provide LoneStar Heart Inc. with design and development services for the minimally invasive delivery system for Algisyl-LVR, an implantable biopolymer for the treatment of dilated cardiomyopathy.

LoneStar Heart is developing a trio of technologies with the potential to restore the heart wall structure and prevent or reverse the progression of advanced heart failure. "This development collaboration will allow LoneStar Heart to focus on their core expertise, which is further developing their Algisyl-LVR technology while relying on Xeridiem for the engineering and design control infrastructure. Essentially Xeridiem will be acting as LoneStar Heart's development team," said Joseph Lee, president of Xeridiem.

Xeridiem designs, develops and manufactures single-use medical devices focused in gastroenterology, cardiology and urology for established healthcare companies and venture-backed entrepreneurs. Since 1986, Xeridiem, as a silent partner, has enabled major medical device companies and venture-backed entrepreneurs to deliver more than 22 million medical devices used worldwide.

LoneStar Heart Inc. is developing cardiac restorative therapies for patients with heart failure that harness the heart's ability to repair itself. Based on its integrated cardiomechanical and biomolecular technologies, the privately held company is advancing a broad portfolio of products to restore the failing heart's structure and function in collaboration with the Texas Heart Institute, the University of Texas Southwestern Medical Center and a global network of leading clinicians. These products include Algisyl-LVR, cardiac stem-cell modulators, and cellular and genetic therapies delivered as standalone treatments, or in combination with the company's proprietary biopolymer matrix system.

For more information: www.xeridiem.com

Related Content

Example of an aortic valve CT imaging workup for TAVR valve sizing and assessing access routes. This patient has an aneurysm in the aortic arch. Image from GE Healthcare.

Example of an aortic valve CT imaging workup for TAVR valve sizing and assessing access routes. This patient has an aneurysm in the aortic arch. Image from GE Healthcare.

Feature | Structural Heart | August 12, 2019 | Ashish Pershad, M.D., and Kenith Fang, M.D., FACS
As we usher in a new era for treating patients with aortic stenosis, we have been reflecting on the evolution of the
University of Michigan Partnership Guides New Approach to Acute Aortic Dissection
Feature | Structural Heart | July 18, 2019
When a patient comes to the hospital with acute type A aortic dissection (ATAAD), a tearing of the inner lining of the...
FEops HEARTguide Wins CSI Highlight of the Year Award
News | Structural Heart | July 05, 2019
FEops announced that FEops HEARTguide was the winning entry at CSI Frankfurt 2019 voted on by physician attendees for...

William O'Neill, M.D., and Adam Greenbaum, M.D., perform a transcatheter aortic valve replacement (TAVR) procedure in the cath lab at Henry Ford Hospital in Detroit.

Podcast | Structural Heart | May 31, 2019
A discussion with William O...
Overlay Init